A Phase I/II Single-arm Trial of Azenosertib (ZN-c3) Combined With Carboplatin and Pembrolizumab in Patients With Metastatic Triple-negative Breast Cancer (ZAP-IT)

Conditions: Breast Cancer; Breast Cancer Female; Triple Negative Breast Cancer; Hormone Receptor Negative Malignant Tumor Breast Triple; HER2-negative Breast Cancer Interventions: Drug: Azenosertib; Drug: Carboplatin; Drug: Pembrolizumab Sponsors: Filipa Lynce, MD; Merck Sharp& Dohme LLC; Zentalis Pharmaceuticals Not yet recruiting

https://clinicaltrials.gov/study/NCT06351332

Source: ClinicalTrials.gov - April 8, 2024 Category: Research Source Type: clinical trials